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ABSTRACT
Background: The rapid antimicrobial susceptibility testing (AST) performed on urine samples 
would guide the adequate choice of antibiotics for obtaining better treatment outcomes in 
patients. Our study aimed to evaluate the performance of the modified-EUCAST (European 
Committee on Antimicrobial Susceptibility Testing) rapid direct AST on urine samples.
Methods: From >2,000 urine samples, a total of 128 urine samples containing bacterial 
counts of ≥2 × 104 CFU/mL with a uniform bacterial shape were initially included based 
on flow cytometry (Sysmex UF-1000i, Japan) and Gram staining, respectively. A total of 103 
samples showing the presence of Enterobacteriaceae were finally selected in this study. The 
urine samples were directly inoculated on Mueller-Hinton agar, which was used in the current 
EUCAST rapid direct AST on blood samples. The size of the growth inhibition zones around 
antimicrobial disks was measured using a digital scanner (BIOMIC vision analyzer, Giles 
scientific, USA) and further confirmed by visualization with naked eyes after incubation for 4, 
6, and 8 hours. The AST interpretations were compared to those of the conventional VITEK 2 
AST system (bioMérieux, France) and the discrepancies between both tests were confirmed 
with the E-test.
Results: The antibiotics, namely ampicillin, cefazolin, aztreonam, ceftazidime, cefotaxime, 
cefoxitin, cefepime, gentamicin, ciprofloxacin, and cotrimoxazole showed excellent 
correlations with modified-EUCAST rapid direct test and conventional ASTs with >0.75 
weighted kappa values. The categorical agreement of the rapid direct AST was 1,442 (93.3%), 
with 76 (4.9%) minor error, 9 (0.6%) major error and 18 (1.2%) very major error, implicating 
the reliability of this method for clinical application.
Conclusion: Performing the modified-EUCAST rapid direct AST on urine samples can predict 
reliable AST results within 8 hours. The rapid direct AST can help the physicians to initiate 
adequate antimicrobial treatment for urinary tract infections.
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INTRODUCTION
Urinary tract infections (UTIs) are a medical threat with the high morbidity of 150 million people 
worldwide a year [1]. Among the bacteria and fungi causing UTIs, Enterobacteriaceae is the most common 
[2]. Especially, Escherichia coli cause 80% of the uncomplicated UTI [3]. UTIs like other infections are 
treated with broad-spectrum antibiotics which consequently lead to an increase of resistance. Hence, the 
rapid antimicrobial susceptibility testing (AST) would increase the adequate choice of antibiotics for the 
better outcome of the patients [4]. Disk diffusion methods and commercial broth micro dilution kits are 
widely used for antimicrobial susceptibility testing in many clinical settings [5]. To ensure accurate and 
timely antimicrobial therapy we need rapid AST methods as it takes 2 to 3 days from the sample collection 
to the AST results by using the conventional methods [6].
To speed up the AST results, many methods have been developed such as Vitek Classic (bioMérieux, 
Marcy L�E t̀oile, France), the more automated VITEK 2 (bioMérieux) and Microscan Walkaway (Dade-
Behring Microscan, Sacramento, CA, USA), and Phoenix system (BD Diagnostic Systems, Sparks, MD, 
USA) [7]. Despite the introduction of these methods, many laboratories in low-income settings cannot use 
them due to their high cost [8]. Currently, European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) published a guideline for rapid AST using disk diffusion methods in blood culture. But, neither 
EUCAST nor CLSI (Clinical and Laboratory Standards Institute) has approved the guideline for rapid AST 
in urine, yet. Hence, we aimed to expand the EUCAST rapid AST from blood to urine culture.
Urine culture method is totally different with blood culture. For urine culture, semi-quantitation for 
bacterial pathogen using calibrated loop is recommended. The most commonly used criterion to define 
significant bacteriuria is �≥105 colony forming unit/mL of urine�. Compared to this, blood culture needs 
more sensitive methodology using enrichment broth. In each broth bottles, 5-10 mL of blood was 
inoculated to recover the bacterial pathogen.
Many papers on reducing the turnaround time of antimicrobial susceptibility testing have been published 
[9], however, limited studies have been done on short incubation time using disk diffusion directly on urine 
samples. Our study aimed to expand the sample scope and to compare the performance of EUCAST rapid 
direct disk diffusion AST on urine samples within 8 hr incubation with the conventional AST method.
MATERIALS AND METHODS
Specimen collection
The study was carried out in the clinical microbiology laboratory of Severance Hospital from August to 
November 2019. Urine samples analysis was done by flow cytometry (Sysmex UF-1000i, TOA Medical 
Electronics, Kobe, Japan) followed by Gram stain. Samples were included in the study only if it contained 
≥ 20,000 bacteria/ml plus the presence of monobacterial Gram-negatives on microscopy. This criteria of 2 
× 104 CFU/mL was from the internal validation to have a visible bacterial growth after 8 hours incubation. 
In detail, using the E. coli ATCC25922 strain, we prepared different dilutions (106, 105, 104 CFU/mL) using 
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culture negative urine. Spiked samples were cultured to check how well the growth will be shown. By 
using the samples showing sufficient growth, the cut off value from Sysmex UF-1000i was set for positive 
sample to be included in our study.
Modified-EUCAST rapid direct AST and species identification
128 urine samples fulfilling the criteria were preselected. Modified-EUCAST rapid direct ASTs were 
performed immediately or kept at 4°C for no longer than 24 hours before testing depending on the reception 
time. The identification of all isolates included in our study was performed by using MALDI-TOF MS 
system, ASTA Micro IDSys (ASTA Inc., Suwon, Korea) according to the manufacturer�s recommendation.
For the quality control, E. coli ATCC25922 strain was mixed in sterile urine samples. They were diluted 
100-,1000- fold to achieve the starting concentrations of 106, 105 CFU/mL, and were inoculated on the 
Mueller-Hinton agar (MHA) plate using a spreader. Antimicrobial disks, ampicillin, cefazolin, ertapenem, 
cefepime, cefotaxime, ceftazidime, cefoxitin, aztreonam, trimethoprim-sulfamethoxazole, amikacin, 
gentamicin, piperacillin-tazobactam, tigecycline, ciprofloxacin, imipenem (Becton, Dickinson and 
Company, Sparks, MD, USA), were applied and pressed firmly onto the agar surface with sterile forceps. 
The 15 antibiotics were selected since they were in VITEK 2 AST cards for Enterobacteriaceae in the 
clinical microbiology laboratory.
The sample volume, suggested by EUCAST for direct rapid AST in blood [10], was depending on plates 
size. Hence, 130 μL and 350 μL of the sample were taken and spread by using cotton swab on the 90 mm- 
and 150 mm-diameter MHA, respectively. The plates were incubated at 35±1°C and read on the same day 
after 8 hours of incubation. The images of inhibition zones were taken and recorded using a digital scanner 
(BIOMIC vision analyzer, Giles scientific, DC, USA) and confirmed by naked eyes. The interpretations of 
AST results were performed following the CLSI breakpoints. However, in tigecycline, we used EUCAST 
breakpoint since there is no CLSI breakpoint for Enterobacteriaceae.
Conventional urine culture and AST
The urine sample was inoculated on both blood agar and MacConkey agar plates. Plates were incubated 
at 35°C overnight. The colonies on agar plate were counted and identified using ASTA Micro IDSys. A 
standardized 0.5 McFarland suspension was prepared and N224 VITEK 2 cards (bioMérieux, Durham, 
NC, USA) for AST were inoculated following the manufacturer recommendation. Interpretation of AST 
was performed following the criteria of the CLSI [11].
Comparison of modified-EUCAST rapid direct methods and conventional 
AST
Results from both methods were compared by measuring the agreement kappa with 95% confidence 
interval analyzed by R studio version 3.3.3. Weighted kappa ranging from 0.75 is classified as excellent, 0.40 
to 0.75 as fair to good, and below 0.40 as poor according to Fleiss [12]. The MIC discrepancies showing 
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major and very major errors were further confirmed by E-test (bioMérieux SA, Marcy-L�E�toile, France) 
with samples kept in freezer -70°C. Susceptibility results obtained by E-test were used as the golden 
standard.
RESULTS
We have screened >2,000 urine samples by using flow cytometry and gram stain during the study period. 
128 urine samples were preselected, and 103 samples grown with Enterobacteriaceae were selected (Fig. 
1). They were distributed as 68 E. coli (66%), 17 Klebsiella pneumoniae (16.5%), 5 Citrobacter freundii 
(4.9%), 2 Citrobacter braakii (1.9%), 2 Enterobacter cloacae (1.9%), 2 Klebsiella ocytica (1.9%), 2 Proteus 
vulgaris (1.9%), 2 Klebsiella aerogenes (1.9%), 1 Raoultella ornithinolytica (1%), 1 Proteus mirabilis (1%), 
1 Morganella morganii (1%). Concerning 25 samples excluded, 17 had more than one bacterium grown on 
the plate and 8 exhibited poor growth after 8 hours to be unreadable.
Fig 1. Flowchart of urine samples selection.
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This criteria of 2 × 104 CFU/mL in Sysmex UF-1000i was from the internal validation. Direct 
antimicrobial susceptibility testing on urine form bacteriuria samples (≥ 2 × 104 bacteria/mL) showed 
that the most effective agents were amikacin (98.1%), ertapenem (97.1%), imipenem (96.1%), tigecycline 
(93.2%) and piperacillin-tazobactam (88.3%) (Table 1). The unweighted kappa scores of 1,545 antibiotics-
isolates combinations of modified-EUCAST rapid direct and conventional AST methods ranged from 0.40 
to 0.93. The weighted kappa values were from 0.55 to 0.95. Ampicillin, cefazolin, aztreonam, ceftazidime, 
cefotaxime, cefoxitin, cefepime, gentamicin, ciprofloxacin, cotrimoxazole had excellent correlations 
between modified-EUCAST rapid direct and conventional ASTs with >0.75 weighted kappa value. Others 
including piperacillin-tazobactam, ertapenem, imipenem, and tigecycline, showed a fair to good agreement, 
i.e., 0.68, 0.60, 0.48, and 0.55, respectively.
The overall categorical agreement of the modified-EUCAST rapid direct and the standard ASTs by using 
additional E-tests was 93.2%, with 4.9% minor errors, 0.6% major error and 1.2% very major errors (Table 
2). Concerning major errors observed, 3 (2.9%) were in cefepime. Out of 18 very major errors observed, 5 
(4.9%) were shown in tigecycline, 4 (3.9%) in cefazolin, 3 (2.9%) in piperacillin-tazobactam, and 2 (1.9%) 
in cotrimoxazole.









S I R S I R
Ampicillin 12 3 88 12 0 91 0.83 (0.77 - 1) 0.89 (0.77 - 1)
Piperacillintazobactam 91 8 4 86 8 9 0.66 (0.47 - 0.83) 0.68 (0.50 - 0.86 )
Cefazolin 44 0 59 41 0 62 0.90 (0.81 - 0.99) 0.90 (0.81 - 0.99 )
Aztreonam 65 5 33 67 0 36 0.84 (0.74 - 0.94 ) 0.89 (0.80 - 0.97 )
Ceftazidime 61 14 28 69 1 33 0.74 (0.62 - 0.85 ) 0.84 (0.75 - 0.92 )
Cefotaxime 50 6 47 54 3 46 0.89 (0.81 - 0.97) 0.93 (0.876 - 0.99)
Cefoxitin 77 3 23 70 8 25 0.76 (0.63 - 0.88 ) 0.86 (0.78 - 0.94)
Cefepime 79 0 24 80 6 17 0.73 (0.59 - 0.88 ) 0.80 (0.67 - 0.92 )
Ertapenem 100 2 1 98 1 4 0.49 (0.18 - 0.79 ) 0.60 (0.29 - 0.92)
Imipenem 99 2 2 93 6 4 0.40 (0.08 - 0.73) 0.48 (0.12 - 0.83)
Gentamicin 75 1 27 75 1 27 0.93 (0.85 - 1) 0.95 (0.89 - 1)
Amikacin 101 1 1 103 0 0 - -
Ciprofloxacin 34 21 48 45 10 48 0.76 (0.66 - 0.87 ) 0.85 (0.78 - 0.92)
Cotrimoxazole 56 1 46 57 0 46 0.90 (0.82 - 0.99 ) 0.91 (0.83 - 0.99)
Tigecycline 96 0 7 92 2 9 0.52 (0.26 - 0.77) 0.55 (0.29 - 0.82 )
Abbreviation: EUCAST, European committee on antimicrobial susceptibility testing; AST, antimicrobial 
susceptibility test; S, susceptible; I, intermediate; R, resistant; CI, confidence interval.
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Among 1,545 antimicrobial agents-strain results, 15 were discrepant between modified-EUCAST 
rapid direct AST and conventional AST; 7 E. coli for aztreonam, cefepime, amikacin, cotrimoxazole, 
and gentamicin, 1 K. pneumoniae for tigecycline, 1 M. morganii for tigecycline, and 3 Proteus spp. for 
tigecycline and imipenem (Table 3). However, after reanalysis the AST with E-test, the discrepancies 
reached 2 major and 2 minor errors in E. coli for aztreonam, cefepime, amikacin and 2 very major errors in P. 
vulgaris and P.  mirabilis for tigecycline.
DISCUSSION
The purpose of this study was to evaluate the performance of rapid direct AST on urine compared to 
the standard method using VITEK 2. E. coli and K. pneumoniae were the most predominant isolates 
in bacteriuria with a prevalence of 66%, 16.5%, respectively. EUCAST showed that the rapid AST 
directly from blood culture bottles was validated only for E. coli, K. pneumonia, P. aeruginosa, S. 
aureus, S. pneumoniae, E. faecalis, E. faecium, and A. baumannii. In this study, we did include other 
Enterobacteriaceae, but not Gram-positives and glucose-non fermenters. Hence, the data in the tables 
represents the overall performance of modified-EUCAST in Enterobacteriaceae, which is not confined to E. 
coli and K. pneumoniae.
Table 2. Performance of modified-EUCAST rapid direct AST compared with conventional 
AST
Antimicrobial agents Total
CA MnE ME VME
No. (%) No. (%) No. (%) No. (%)
Ampicillin 103 99 (96.1) 3 (2.9) 0 (0) 1 (1.0)
Piperacillin-tazobactam 103 94 (91.3) 6 (5.8) 0 (0) 3 (2.9)
Cefazolin 103 98 (95.1) 0 (0) 1 (1.0) 4 (3.9)
Aztreonam 103 96 (93.2) 5 (4.8) 1 (1.0) 1 (1.0)
Ceftazidime 103 89 (86.4) 13 (12.6) 1 (1.0) 0 (0)
Cefotaxime 103 97 (94.2) 5 (4.8) 1 (1.0) 0 (0)
Cefoxitin 103 94 (91.2) 9 (8.7) 0 (0) 0 (0)
Cefepime 103 94 (91.3) 6 (5.8) 3 (2.9) 0 (0)
Ertapenem 103 100 (97.1) 2 (1.9) 0 (0) 1 (1.0)
Imipenem 103 96 (93.2) 6 (5.8) 0 (0) 1 (1.0)
Gentamicin 103 101 (98.1) 2 (1.9) 0 (0) 0 (0)
Amikacin 103 101 (98.1) 1 (1.0) 1 (1.0) 0 (0)
Ciprofloxacin 103 88 (85.4) 15 (14.6) 0 (0) 0 (0)
Cotrimoxazole 103 100 (95.1) 1 (1.0) 0 (0) 2 (1.9)
Tigecycline 103 95 (91.3) 2 (1.9) 1 (1.0) 5 (4.9)
TOTAL 1,545 1,442 (93.3) 76 (4.9) 9 (0.6) 18 (1.2)
Abbreviation: EUCAST, European committee on antimicrobial susceptibility testing; AST, 
antimicrobial susceptibility test; CA, categorical agreement; MnE, minor error; ME, major 
error; VME, very major error.
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Resistant rates to ampicillin, cefazolin, cefotaxime, ciprofloxacin, and cotrimoxazole were more than 
40 of the tested strains, whereas piperacillin-tazobactam, ertapenem, imipenem, amikacin, and tigecycline 
were found to be the most active in vitro (Table 1). Our study showed excellent results compared to 
the conventional AST overall. Weighted kappa values of the results from the comparisons between 
both methods showed an excellent concordance for some antibiotics, however, others like piperacillin-
tazobactam, ertapenem, imipenem, and tigecycline, showed a fair to good agreement (0.68, 0.60, 0.48, 0.55), 
respectively. Piperacillin-tazobactam or carbapenem was usually recommended for acute pyelonephritis 
patients with severe conditions such as severe sepsis or septic shock. Therefore, rapid direct AST can help 
the physicians to start adequate antimicrobial treatment. Kappa statistics of amikacin was not calculated 
since conventional AST categorized all samples into a single level, i.e, susceptible. Specifically, for 
cefazolin, cefotaxime, gentamicin, and cotrimoxazole, modified-EUCAST rapid direct AST showed over 
0.9 weighted kappa values.
Furthermore, the overall agreement and error rates were within the acceptable limits which gives it the 
credential to be adopted into routine microbiology laboratory workflow since it helps us to save more than 
24 hours (Table 2). According to Jorgensen criteria, the rates of VME (very major error) and the sum of 
ME (major error) and MnE (minor error) should be < 3%, < 7% respectively [13]. Cefoxitin, gentamicin, 
and ciprofloxacin did not show neither major error nor very major error. When considering every single 
Table 3. Summary of discrepancies in 13 strains showing discrepant results between modified-EUCAST rapid direct 
and conventional ASTs
Species Antimicrobial agent Modified-EUCAST rapid direct AST
Conventional 
AST
MIC by E-test 
(μg/mL) Interpretation
Escherichia coli Aztreonam R S 0.5 ME
Escherichia coli Cefepime R S 4 MnE
Escherichia coli Cefepime R S 8 MnE
Escherichia coli Amikacin R S 4 ME
Escherichia coli Cotrimoxazole S R 1.5 Agreement
Gentamicin R S 32 Agreement
Aztreonam R S 48 Agreement
Escherichia coli Cotrimoxazole R S ≥32 Agreement
Escherichia coli Cotrimoxazole R S 48 Agreement
Klebsiella pneumoniae Tigecycline† S R 2 Agreement
Morganella morganii Tigecycline S R 1.5 Agreement
Proteus vulgaris* Tigecycline S R 16 VME
Proteus vulgaris* Tigecycline S R 2 Agreement
Proteus mirabilis* Tigecycline S R 24 VME
Imipenem S R 1 Agreement
*The most very major errors were noted in tigecycline for P. vulgaris and P. mirabilis. †The FDA MIC breakpoints 
for susceptible (≤ 2 μg/mL), intermediate (4 μg/mL), and resistant (≥ 8 μg/mL) were used to categorize tigecycline 
susceptibility in Enterobacteriaceae strains.
Abbreviation: EUCAST, European committee on antimicrobial susceptibility testing; AST, antimicrobial susceptibility 
test; MIC, minimal inhibitory concentration; R, resistant; S, susceptible; ME, major error; MnE, minor error; VME, 
very major error.
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antibiotic, the results of ciprofloxacin, cefoxitin, cefepime, cefazolin, ceftazidime, tigecycline exceeded the 
acceptable limits. However, overall ME was 1.2% and the sum of ME and MnE were 5.5% in this study. 
These findings implicated its usefulness to report rapid AST results of many antibiotics in clinical urine 
samples.
The modified-EUCAST rapid direct AST is more likely to give the real image of population AST 
because it was performed with the whole bacterial population in the sample rather than with a single colony 
which was picked on the plate. Therefore, the results are likely to be clinically relevant [9]. However, the 
errors in the case of polymicrobial microscope findings are quite high thus it is suggested to be done in 
monobacterial microscopy findings only [14]. Numbers of urine samples (13.2%, 17/128) have been 
excluded from this study due to the mixed microscopy of  ≥2 Gram-negative bacterial findings.
In a study done by Perillaud et al., the direct AST compared to the conventional disk diffusion AST 
showed 97.9% categorical agreement, 1.5% minor errors, 0.3% major error, and 0.3% vary major error 
were found [15], which were quite comparable with the results of this study. Though the AST of rapid 
method seems not to be complete, the result generated in a relatively short period compared to the 
conventional method and thus can help the physician give the appropriate empirical therapy [9]. For some 
of the discrepancies, inhibition zones were close to clinical breakpoints, where a slight difference in mm 
zone of diameter would yield to a major or very major error. The agreement for each antimicrobial agent 
exceeds 85% in all isolates studied.
The limitation of our study was the spectrum of test strains, because we included Enterobacteriaceae, but 
not other Gram-negative bacilli, such as P. aeruginosa. Relatively slow growing bacteria do not allow the 
reading of inhibition zone diameter before 8 hours incubation. Multiple bacterial infections with similar 
colony appearance would be also a huddle to this rapid AST method although it is rare, because the 
discrimination of different isolates on single plate would not be possible by naked eyes. Thus it can make an 
error in inhibition zone diameter measure.
In conclusion, despite some errors and unstandardized inoculum size, we showed the modified-EUCAST 
rapid direct AST on urine would be reliable in Enterobacteriaceae. The rapid AST reports by using direct 
susceptibility testing in UTIs can shorten the time for the start of adequate antimicrobial treatment.
요약
배경: 소변 검체 배양 후 신속하게 항균제 감수성 결과를 얻는 것은 적절한 항균제로 환자를 치료
하기 위하여 중요하다. 본 연구에서는 EUCAST가 제시한 혈액 신속 직접 항균제 감수성 검사법
을 뇨 검체에서 적용하여 평가하고자 하였다.
방법: 유세포 분석기(Sysmex UF-1000i, Japan)와 그람염색법으로 선별검사 후, 2 × 104 bacteria/ mL 
이상의 단일 세균 형태를 갖는 103개의 뇨 검체를 대상으로 하였다. EUCAST 혈액 신속 직접 항
균제 감수성 검사법과 동일하게, Mueller-Hinton 우무 배지에 뇨 검체를 직접 접종한 후, 항균제 디
스크를 부착하였다. 이를 4, 6, 8 시간 후에 항균제 디스크 주변 균증식 억제대 지름을 육안과 디지
털 스캐너(BIOMIC vision analyzer, Giles scientific, USA)로 측정하였다. 항균제 감수성 검사의 해석
은 기존 VITEK 2 시스템과 비교하였으며, 결과가 불일치한 경우 E-test법으로 확인하였다.
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결과: Ampicillin, cefazolin, aztreonam, ceftazidime, cefotaxime, cefoxitin, cefepime, gentamycin, 
ciprofloxacin, cotrimoxazole에서는 신속 직접 항균제 감수성 검사법과 기존의 항균제 감수성 검
사법 간의 weighted kappa value가 0.75 이상으로 우수한 상관관계를 보였다. 1,545개 균주-항균제 
감수성 시험 결과에서, 신속 직접 항균제 감수성 검사법의 categorical agreement는 1,442 (93.3%), 
minor errors는 76 (4.9%), major error는 9 (0.6%) , very major errors는 18 (1.2%)으로 신뢰성이 있었다.
결론: 신속 직접 항균제 감수성 검사법으로 Enterobacteriaceae를 포함한 뇨 검체에서 8시간 내에 
신뢰할 수 있는 항균제 감수성 검사 결과를 얻을 수 있었다. 신속 직접 항균제 감수성 검사법은 요
로감염에서 임상의가 적절한 항균제 치료를 시작하는데 유용할 것으로 판단하였다.
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